Market Report Source

Overview

Introduction

GTC Biotherapeutics is engaged in the development, production and commercialization of therapeutic proteins expressed and purified from the milk of transgenic animals such as goats and cattle. ATryn, the company’s major product, is a recombinant human antithrombin produced in the milk of transgenic goats.

Scope

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

GTC develops, produces, and commercializes therapeutic proteins through transgenic animal technology. In addition to ATryn, GTC is working with LFB Biotechnologies to develop recombinant forms of human factor VIIa and a CD20 monoclonal antibody. Total revenues of the company witnessed decline at a CAGR of 11% during 2002-2006, from $10 million to $6 million. It derives its revenues from collaborative agreements which include non-refundable license fees, funding of research and development, payments based upon the achievement of certain milestones and royalties. Between 2006 and 2010, the company’s revenues are forecasted to increase at a CAGR of 22% from $6 million to $13 million. There will be an absolute growth of +$7 million in the company’s total revenues by 2010. The company is expected to receive all of its revenues through collaborative agreements with its partners.

Reasons to Purchase

Access all the important information and analysis on the company in a single report Understand company’s strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company’s adjusted five year financial data along with key ratios and market capitalization.

Table of Contents

Overview
Catalyst
Summary
Company Structure
Company Overview and Key Facts
Business Description
History
Company Financials
Stock Market Performance
P&L
Balance Sheet
Cash Flow
Business Segment Performance
Products & Services
Pipeline Products
AC Forecast Product Sales
Competitors and Strategic Business Relationships
Key Competitors
Key Suppliers
Key Clients
Shareholding Structure
Strategy
Company View
Corporate Strategy
SWOT Analysis
Overview
Strengths
Weaknesses
Opportunities
Threats
Value Chain Analysis
Overview
Discovery and Product Development
Manufacturing
Scorecard
Overview
Scorecard Analysis
Key Employees
List of Key Employees
Key Employee Biographies
Financial and Operational Overview
Financial and Operational Overview

APPENDIX
Ask the analyst
Datamonitor consulting
Disclaimer

FIGURES
Figure 1: GTC Biotherapeutics – Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)

TABLES
Table 1: GTC Biotherapeutics – Key Facts
Table 2: GTC Biotherapeutics – Year-End Share Price and Market Capitalization, 2002-2006 ($)
Table 3: GTC Biotherapeutics – Key Events Impacting Share Price Performance
Table 4: GTC Biotherapeutics – Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
Table 5: GTC Biotherapeutics – Operating Cost Ratio Analysis, 2002-2006 (% of total revenues)
Table 6: GTC Biotherapeutics – Balance Sheet, 2002-2006 ($ Mn)
Table 7: GTC Biotherapeutics – Cash Flow, 2002-2006 ($ Mn)
Table 8: GTC Biotherapeutics – Revenue Breakdown, 2002-2006 ($ Mn)
Table 9: GTC Biotherapeutics – In-house Pipeline Products
Table 10: GTC Biotherapeutics – Collaboration Pipeline
Table 11: GTC Biotherapeutics- Key Strategic Revenues, 2006-2010 ($ Mn)
Table 12: GTC Biotherapeutics – Key Competitors
Table 13: GTC Biotherapeutics – Key Suppliers
Table 14: GTC Biotherapeutics – Key Clients
Table 15: GTC Biotherapeutics – Key Shareholders
Table 16: GTC Biotherapeutics – SWOT Analysis Summary
Table 17: GTC Biotherapeutics – Value Chain Analysis
Table 18: GTC Biotherapeutics – Scorecard
Table 19: GTC Biotherapeutics – Key Employees
Table 20: GTC Biotherapeutics – Financial and Operational Overview